The company also shared earnings expectations for 2024 at the J.P. Morgan Healthcare Conference.
Dexcom plans to launch new CGM this summer for people who don’t take insulin Read More »
Startups turned to “creative” funding mechanisms like unlabeled and silent rounds to buy time in 2023, but those strategies likely won’t work again this year, according to a report by Rock Health.
Digital health funding reached lowest level since 2019 last year: report Read More »
Following the FDA’s November announcement of an investigation into 20 cases of T cell lymphoma recipients of CAR-T therapies, a cadre of cancer and cell therapy leaders published their assessment in Nature.
CAR T Cell Therapy Is a Comparatively Low-Risk Cancer Treatment: Industry Experts Read More »
The Alliance for Regenerative Medicine predicts up to 17 cell and gene therapy approvals this year and defends high prices, while FDA’s Peter Marks expresses concern about manufacturing costs.
Gene Therapy Approvals Expected to Ramp Up in 2024 Amid Manufacturing, Cost Challenges Read More »
Tousi is in charge of commercializing the lead liquid biopsy from a company that could compete with Grail, the multi-cancer early detection test maker Illumina plans to divest.
Susan Tousi leaves Illumina to become CEO of liquid biopsy firm Delfi Read More »
Si estás considerando la posibilidad de trabajar en el extranjero, Canadá se presenta como un destino laboral atractivo en 2023. Este país, conocido por su calidad de vida, oportunidades profesionales y diversidad cultural, ofrece numerosas posibilidades para aquellos que desean …
Descubre las Oportunidades: Cómo Trabajar en Canadá en 2023 Read More »
The executive spoke with Biospace about Codagenix’s nasal COVID-19 spray vaccine, the COVID market, and how the company fits into the broader infectious disease space.
JPM 2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development Read More »
Following the FDA’s approval of the program, PhRMA is once again suing to block Florida from importing prescription drugs from Canada.
Industry Group Prepares Another Lawsuit Against Florida’s Drug Importation Plan Read More »
Following in the footsteps of Novartis, J&J and Merck, GSK jumped into the J.P. Morgan dealmaking frenzy Tuesday, picking up respiratory and inflammation-focused Aiolos Bio.
GSK Puts $1.4B on the Line in Aiolos Acquisition to Boost Asthma Pipeline Read More »
Vertex still has an ongoing diabetes partnership with CRISPR, which gives it a non-exclusive license to the latter’s platform to develop a potential cure for type 1 diabetes.
Vertex’s Viacyte Backs Out of CRISPR Diabetes Deal Read More »
